Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

NCT02694224 is registered in ClinicalTrials.gov with Clinica Universidad de Navarra, Universidad de Navarra as lead sponsor.

NCT NCT02694224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02694224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
Lead sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2016
Completion date
December 31, 2018
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer